Vitruvias Therapeutics Competitors and Similar CompaniesClear all
Vitruvias Therapeutics's competitors and similar companies include Expansion Therapeutics, Neuron23, Bluebird Bio and Sarepta Therapeutics.
 Vitruvias Therapeutics Vitruvias Therapeutics is a generic pharmaceutical company with a focus on developing niche topical generic products that are sold only by prescription. |  Expansion Therapeutics Expansion Therapeutics is a drug discovery and development company pursuing a potential of small molecule medicines for RNA-mediated diseases. |  Sarepta Therapeutics Sarepta Therapeutics is a biopharmaceutical company specializing in the discovery and development of RNA-targeted therapeutics, gene therapy and, other genetic therapeutic modalities for the treatment of rare diseases. | |||
Founding Date | Founding Date 2013 | Founding Date 2016 | Founding Date 2018 | Founding Date 1992 | Founding Date 1980 |
Type | Type Private | Type Private | Type Private | Type Public | Type Public |
Tags | |||||
Locations | Locations Auburn, US HQ | Locations Jupiter, US HQ | Locations South San Francisco, US HQ | Locations Somerville, US HQ | Locations Cambridge, US HQ Dublin, IE Zug, CH Providence, US |
Employees | Employees 525% increase | Employees 1611% decrease | Employees 427% decrease | Employees 32338% decrease | Employees 1,31413% increase |
Valuation ($) | Valuation ($) N/A | Valuation ($) N/A | Valuation ($) 507.1 m | Valuation ($) 95.4 m | Valuation ($) 12.4 b |
Financial | |||||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) N/A | Revenue (est.) N/A | Revenue (est.) $83.8m (FY, 2024) | Revenue (est.) $2.2b (FY, 2025) |
Cost of goods | Cost of goods N/A | Cost of goods N/A | Cost of goods N/A | Cost of goods $89.4m (FY, 2024) | Cost of goods $25.5m (FY, 2025) |
Gross profit | Gross profit N/A | Gross profit N/A | Gross profit N/A | Gross profit ($5.6m) (FY, 2024) | Gross profit $2.2b (FY, 2025) |
Net income | Net income N/A | Net income N/A | Net income N/A | Net income ($240.7m) (FY, 2024) | Net income ($713.4m) (FY, 2025) |
Funding | |||||
Latest funding round | Latest funding round $ 11.5m (over 8 years ago) | Latest funding round $ 55.3m (over 8 years ago) | Latest funding round $ 80m (over 5 years ago) | Latest funding round N/A | Latest funding round N/A |
Total funding raised | Total funding raised $ 12.5m | Total funding raised $ 55.3m | Total funding raised $ 113.5m | Total funding raised $ 409m | Total funding raised N/A |
For sources of this data, please see the company profile
View Company Profiles
Expansion Therapeutics
HQ
Jupiter, US
Employees
16↓ 11% decrease
Expansion Therapeutics is a drug discovery and development company pursuing a potential of small molecule medicines for RNA-mediated diseases.
View company
Neuron23
HQ
South San Francisco, US
Employees
42↓ 7% decrease
Neuron23 is a biotechnology company that develops medicines for genetic disorders.
View company
Bluebird Bio
HQ
Somerville, US
Employees
323↓ 38% decrease
Bluebird Bio is a developer of gene therapies for severe genetic diseases.
View companySarepta Therapeutics
HQ
Cambridge, US
Employees
1,314↑ 13% increase
Sarepta Therapeutics is a biopharmaceutical company specializing in the discovery and development of RNA-targeted therapeutics, gene therapy and, other genetic therapeutic modalities for the treatment of rare diseases.
View company